National Health Act 1953 - Determination under subsection 85AB(1) and 85AC(1) - drugs on F1 and drugs in Part A of F2 (No. PB 95 of 2007)

Overview

The Determination — drugs on F1 and drugs in Part A of F2 (PB 95 of 2007) was enacted to address the need for a comprehensive list of drugs that are subject to specific regulations under the National Health Act 1953. This legislative instrument, made under subsections 85AB(1) and 85AC(1) of the National Health Act, was introduced by the Australian Government and outlines the drugs that fall under specific categories, namely F1 and Part A of F2. The primary objective of this determination is to ensure that these drugs are appropriately managed and regulated, facilitating better health outcomes and compliance with national health standards. The determination was first brought into effect on 1 December 2007 and has since been amended multiple times to incorporate new drugs and reflect changes in health policy and medical advancements. The continuous updates to this list underscore the dynamic nature of health regulations and the importance of keeping the legislative framework current and responsive to emerging health needs.

Scope and Application

The Determination — drugs on F1 and drugs in Part A of F2 (PB 95 of 2007) is a legislative instrument made under subsections 85AB(1) and 85AC(1) of the National Health Act 1953. This instrument outlines the listing of specific drugs on the First Schedule (F1) and Part A of the Second Schedule (F2) of the National Health (Pharmaceutical Benefits) Regulations 1977. The listing of these drugs impacts their eligibility for subsidies under the Pharmaceutical Benefits Scheme (PBS) in Australia. The legislation applies to pharmaceutical entities and individuals who seek reimbursement for these drugs through the PBS. The scope of this legislative instrument is national, as it is enacted under the Commonwealth's authority through the National Health Act 1953. The instrument commenced on 1 December 2007 and has since been amended several times to update the list of drugs, with amendments taking effect on various dates as specified in the legislative instrument. No specific exclusions or thresholds are mentioned in the text, but the inclusion of drugs on F1 and F2 lists them as eligible for subsidies under the PBS. The application of this Act can be further refined through subordinate instruments, which provide detailed regulations and amendments to the list of drugs on F1 and F2.

Key Provisions

The Determination — drugs on F1 and drugs in Part A of F2 (PB 95 of 2007) specifies which drugs are to be included on the First and Second Formularies (F1 and F2) under the National Health Act 1953. Specifically, Section 2 lists 26 drugs that are on F1, and Section 3 lists 23 drugs that are on F2, as well as in Part A of F2. These sections, therefore, outline the specific medications that are approved for subsidy under the Pharmaceutical Benefits Scheme (PBS). The Act imposes certain obligations on the parties involved, including the requirement for pharmaceutical manufacturers and suppliers to ensure that the drugs listed on F1 and F2 are available for prescription and supply under the PBS. Healthcare providers must also adhere to the guidelines and criteria set out in the Act when prescribing these medications to patients. Failure to comply with the provisions of the Act can result in both civil and criminal penalties. For example, individuals or entities found to be in breach of the Act may face fines, imprisonment, or both. The specific penalties depend on the nature and severity of the breach. For instance, knowingly supplying or prescribing a drug that is not listed on F1 or F2 could result in fines up to $22,000 and/or imprisonment for up to two years. More serious breaches, such as those involving fraud or deception, can attract even harsher penalties. Additionally, the Act provides for the recovery of costs associated with the investigation and prosecution of offences under the Act.